The Latest Breaking News from RBC Capital

RBC Capital analysts recommend buying Pactiv Evergreen (PTVE) amid these uncertain macroeconomic conditions because of its dividend payments and growth potential. So, let’s discuss what makes the stock a solid investment now….

RBC Capital analyst Ashish Sabadra lowered the price target for Verisk Analytics, Inc. (NASDAQ:VRSK) to $210 from $227 while maintaining the Outperform rating on the shares. The analyst expects 2Q22 revenues modestly below consensus as the tailwinds from strong insurance premium growth, international travel, and a potential uptick in auto insurance are more than offset…

RBC Capital has decided to maintain its Underperform rating of Enerpac Tool Group (NYSE:EPAC) and lower its price target from $19.00 to $18.00. Shares of Enerpac Tool Group are trading down 0.86% over the last 24 hours, at $18.34 per share.

Analysts lauded CarMax Inc's (NYSE:KMX) Q1 beat while also pointing out the macro concerns. RBC Capital analyst Steven Shemesh maintained CarMax with an Outperform and raised the price target from $104 to $108 in a note titled, "F1Q'23 Follow-Up – Navigating Volatility Well." KMX's results were broadly in line with expectations, Shemesh noted.  He expected the inflationary…

RBC Capital analyst Brad Erickson dove in deep with SMB-focused advertising agencies for near-term spending feedback and the ever-evolving competitive landscape across different ad channels. 

Wedbush analyst Nick Setyan lowered the price target on Darden Restaurants Inc (NYSE:DRI) to $122 (3% upside) from $140 and kept a Neutral rating on the shares. The analyst noted that FY23 guidance is predicated on normalization in inflation trends in the second half and has lowered his FY23 EPS estimate to $7.60 from $8.41…

RBC Capital has decided to maintain its Outperform rating of Accenture (NYSE:ACN) and lower its price target from $435.00 to $357.00. Shares of Accenture are trading up 2.58% over the last 24 hours, at $293.21 per share. A move to $357.00 would account for a 21.75% increase from the current…

Upgrades

RBC Capital analyst Mike Dahl further reduces estimates and price targets for Homebuilders & Building Products companies as housing demand declines. The analyst expects further deterioration after the most recent jump in rates (+50 bps past 2 weeks and +270 bps YTD).

RBC Capital says Edgewise Therapeutics Inc's (NASDAQ:EWTX) interim results from the ARCH study of EDG-5506 in Becker Muscular Dystrophy (BMD) improve reward/risk into October functional readout at 15 mg, which can help further de-risk the asset into the phase 2 BMD and Duchenne muscular dystrophy (DMD) studies. The analysts believe stable patient NSAAs in October…

Upgrades